Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 3rd Candidate for JMA President
February 15, 2010
- Takeda to Work Out New Mid-Term Management Plan 1 Year Ahead of Schedule
February 15, 2010
- Daiichi Sankyo Applies for Laninamivir in Japan
February 15, 2010
- JAID Compiles Guidance for Selection of Anti-Flu Drugs
February 15, 2010
- Chugai Aims to Lead Market in 3 Fields: Mr Nagayama
February 15, 2010
- Urief Approved in Europe: Kissei
February 15, 2010
- Smoking Cessation Aids Should Be Covered by Insurance in Young Smokers
February 15, 2010
- US Sales of Prograf Down 17.6% Following Generic Entry
February 15, 2010
- Bendamustine Approved in Singapore: SymBio
February 15, 2010
- Kowa to Launch Livalo Soon in the US
February 15, 2010
- Banyu, Schering-Plough Copromote Mutual Products to Offer New Options for Asthma, Allergy
February 15, 2010
- Astellas to Enter PII for Antibody Drug for Ovarian Cancer
February 15, 2010
- Novartis Aims to Become Top-3 Oncology Company in Japan
February 15, 2010
- Daiichi Sankyo Begins Global PIII Trial for Edoxaban for Prevention of VTE
February 15, 2010
- NBI Aims at RLS to Account for 15% of BI-Sifrol Sales
February 15, 2010
- Application for Eritoran Postponed: Eisai
February 15, 2010
- SSP Revises Full-Year Business Forecasts for FY2009 Upward
February 8, 2010
- H1N1 Vaccine Arepanrix Prequalified by WHO: GSK
February 8, 2010
- Korosho Negotiates Partial Cancellation on Vaccine Import
February 8, 2010
- Actos, Glivec, Herceptin to Be Re-Priced for Market Expansion
February 8, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…